Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
Klaus G ParhoferMedical Department II Grosshadern, University of Munich, GermanyAbstract: Although statins reduce cardiovascular morbidity and mortality further risk reduction is needed. In this respect low HDL-cholesterol concentrations and/or elevated triglyceride concentrations may b...
Main Author: | Klaus G Parhofer |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-11-01
|
Series: | Vascular Health and Risk Management |
Online Access: | http://www.dovepress.com/review-of-extended-release-niacinlaropiprant-fixed-combination-in-the--a3684 |
Similar Items
-
Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
by: Ayman A Hussein, et al.
Published: (2010-04-01) -
Extended Release Niacin-Laropiprant in Patients with Hypercholesterolemia or Mixed Dyslipidemias Improves Clinical Parameters
by: Helen Vosper
Published: (2011-01-01) -
Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed  dyslipidemias and primary hypercholesterolemia
by: Adie Viljoen, et al.
Published: (2010-05-01) -
Effects of extended-release niacin with laropiprant in high-risk patients.
by: Landray, M, et al.
Published: (2014) -
Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia
by: Farnier M, et al.
Published: (2014-05-01)